Method Development and Validation for the determination of Higher Molecular Weight species of Calcitonin Salmon in Calcitonin Salmon injection by High Performance Size Exclusion Chromatography


  • Akhilesh Kumar Kuril Bhagwant University, Sikar Road, Ajmer, Rajasthan, India
  • K. Saravanan Bhagwant University, Sikar Road, Ajmer, Rajasthan, India



Aggregation, Oligomer Higher molecular weight impurities, Multimer, Calcitonin Salmon


Protein aggregation is the process by which misfolded proteins self-assemble into soluble oligomers and insoluble aggregates. An isocratic HP-SEC method was developed in order to determine the protein aggregation in the Calcitonin Salmon injection. Since the label claim of the Calcitonin Salmon in Calcitonin Salmon is 33.33mg/ml at this level of test concentration, no aggregate was observed even with 500 ml injection volume of as such test preparation. Therefore, to detect aggregates or high molecular weight impurities, attempts were made to increase the test concentration of Calcitonin Salmon injection by evaporating the test product under a nitrogen stream and subsequently reconstituting it with a diluent. An isocratic HP-SEC method was developed in order to determine the protein aggregation in the Calcitonin Salmon injection. The chromatographic separation was achieved at SEC column i.e., Insulin, HMWP, 300 x 7.8 mm with 0.1%TFA in mixture of Water: Acetonitrile (70:30) with the flow rate 0.5 ml/min. 100 µl of samples were injected at 40°C column temperature and UV detection occurred at 220 nm. The developed method is highly specific and oligomers are completely separated from the principal peak with USP resolution of 1.5. The developed method was found to be accurate, linear, and precise in the range of 0.092 μg/ml to 300 μg/ml. The method also examined with stress factors such as temperature, light, agitation, freezing, and thawing to identify and study the factors that induces the aggregation of Calcitonin Salmon in Calcitonin Salmon drug product.


Download data is not yet available.


Philo JS. Characterizing the aggregation and conformation of protein therapeutics. American biotechnology laboratory. 2003 Oct;21(11):22-9.

Den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharmaceutical research. 2011 Apr;28:920-33.

Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharmaceutical research. 2003 Sep;20:1325-36.

Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. Journal of pharmaceutical sciences. 2009 Sep 1;98(9):2909-34.

Cromwell ME, Hilario E, Jacobson F. Protein aggregation and bioprocessing. The AAPS journal. 2006 Sep;8:E572-9.

Valerio M, Colosimo A, Conti F, Giuliani A, Grottesi A, Manetti C, Zbilut JP. Early events in protein aggregation: molecular flexibility and hydrophobicity/charge interaction in amyloid peptides as studied by molecular dynamics simulations. Proteins: Structure, Function, and Bioinformatics. 2005 Jan 1;58(1):110-8.

Arakawa T, Timasheff S. The stabilization of proteins by osmolytes. Biophysical journal. 1985 Mar 1;47(3):411-4.

Arakawa T, Bhat R, Timasheff SN. Preferential interactions determine protein solubility in three-component solutions: the magnesium chloride system. Biochemistry. 1990 Feb 1;29(7):1914-23.

Dobson CM. Protein folding and disease: a view from the first Horizon Symposium. Nature Reviews Drug Discovery. 2003 Feb 1;2(2):154-60.

Andya JD, Hsu CC, Shire SJ. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. Aaps Pharmsci. 2003 Jun;5:21-31.

Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF. Aggregation of recombinant human interferon gamma: kinetics and structural transitions. Journal of pharmaceutical sciences. 1998 Sep 1;87(9):1069-76.

Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors affecting short-term and long-term stabilities of proteins. Advanced drug delivery reviews. 2001 Mar 1;46(1-3):307-26.

Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. [16] Inhibition of stress-induced aggregation of protein therapeutics. In Methods in enzymology 1999 Jan 1 (Vol. 309, pp. 236-255). Academic Press.

Mahler HC, Müller R, Frieβ W, Delille A, Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. European journal of pharmaceutics and biopharmaceutics. 2005 Apr 1;59(3):407-17.

Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International journal of pharmaceutics. 1999 Aug 20;185(2):129-88.

Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Current opinion in structural biology. 1998 Feb 1;8(1):101-6.

Marcon G, Plakoutsi G, Chiti F. Protein Aggregation Starting from The Native Globular State1. Methods in enzymology. 2006 Jan 1;413:75-91.

Holm NK, Jespersen SK, Thomassen LV, Wolff TY, Sehgal P, Thomsen LA, Christiansen G, Andersen CB, Knudsen AD, Otzen DE. Aggregation and fibrillation of bovine serum albumin. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2007 Sep 1;1774(9):1128-38.

Makin OS, Serpell LC. Structures for amyloid fibrils, Febs j. 2005 Nov 5; 272(23):5950-61.

Rosenberg AS. Effects of protein aggregates: an immunologic perspective. The AAPS journal. 2006 Sep;8:E501-7.

Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface focus. 2017 Dec 6;7(6):20170030.

Li H, Rahimi F, Sinha S, Maiti P, Bitan G, Murakami K. Amyloids and protein aggregation–analytical methods. Encyclopedia of analytical chemistry. 2009 Sep 15;10(9780470027318):a9038.






Research Article

How to Cite

“Method Development and Validation for the Determination of Higher Molecular Weight Species of Calcitonin Salmon in Calcitonin Salmon Injection by High Performance Size Exclusion Chromatography ”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 16, no. 2, Mar. 2024, pp. 260-6,